Inventor · disambiguated record
Angelika Lüking
Also filed as: LUEKING ANGELIKA · LUKING ANGELIKA · LÜKING ANGELIKA
7 granted patents·15 pending applications·0 citations·filing 2005–2022
70Inventor score
Top patents by PatentIndex Score
22 records- 0161US11609237B2Marker sequences for diagnosing and stratifying systemic sclerosis patientsONCIMMUNE GERMANY GMBH·Filed 2019·Granted Mar 21, 2023·0 cites·11 claims
- 0256US9588115B2Method for the diagnosis of neuromyelitis opticaPROTAGEN AG·Filed 2014·Granted Mar 7, 2017·0 cites·3 claims
- 0355US11860162B2Marker sequences for diagnosing and stratifying SLE patientsONCIMMUNE GERMANY GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·9 claims
- 0453US10036746B2Method for the diagnosis of neuromyelitis opticaPROTAGEN AG·Filed 2017·Granted Jul 31, 2018·0 cites·6 claims
- 0551US10571477B2Marker sequences for diagnosing and stratifying systemic sclerosis patientsPROTAGEN AG·Filed 2015·Granted Feb 25, 2020·0 cites·11 claims
- 0650US2015087548A1Marker sequences for rheumatoid arthritis and use thereofPROTAGEN AG·Filed 2014·Application pending·0 cites
- 0750US2015024962A1Marker sequences for multiple sclerosis and use thereofPROTAGEN AG·Filed 2014·Application pending·0 cites
- 0847US2017009300A1Marker sequences for rheumatoid arthritis and use thereofPROTAGEN AG·Filed 2016·Application pending·0 cites
- 0945US2011184375A1Marker sequence for neurodegenerative diseases and the use thereofPROTAGEN AG·Filed 2008·Application pending·0 cites
- 1045US2010280224A1Marker sequences for multiple sclerosis and use thereofPROTAGEN AG·Filed 2008·Application pending·0 cites
- 1144US2024368672A1Blood matrix as reference material for in-vitro diagnosticsSENSID GMBH·Filed 2022·Application pending·0 cites
- 1243US10746735B2Marker sequences for diagnosing and stratifying SLE patientsPROTAGEN AG·Filed 2015·Granted Aug 18, 2020·0 cites·4 claims
- 1343US2010261881A1Marker sequences for rheumatoid arthritis and use thereofPROTAGEN AG·Filed 2008·Application pending·0 cites
- 1439US2015293120A1Marker sequences for rheumatoid arthritisPROTAGEN AG·Filed 2013·Application pending·0 cites
- 1538US2010331201A1Protein biochip for the differential screening of protein-protein interactionsPROTAGEN AG·Filed 2007·Application pending·0 cites
- 1637US2009124509A1Protein-biochip for validating binding agentsPROTAGEN AG·Filed 2005·Application pending·0 cites
- 1735US2019128884A1Marker sequences for managing the therapy of rheumatoid arthritis patientsPROTAGEN AG·Filed 2017·Application pending·0 cites
- 1832US2019120834A1Marker sequences for rheumatoid arthritisPROTAGEN AG·Filed 2017·Application pending·0 cites
- 1931US2014371098A1Marker sequences for breast cancer and the use thereofPROTAGEN AG·Filed 2012·Application pending·0 cites
- 2028US10677795B2Marker sequences for the diagnosis and stratification of systemic sclerosis patientsPROTAGEN AG·Filed 2015·Granted Jun 9, 2020·0 cites·9 claims
- 2126US2015177247A1Method for identifying marker sequences for gynaecological malignant tumoursPROTAGEN AG·Filed 2015·Application pending·0 cites
- 2222US2009246203A1Method for immunoadsorption by means of autoanitgensLUEKING ANGELIKA·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →